EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention

Jun-Jia Gong iD, I-Hsiu Huang, Yuan-Pin Hung iD, Yi-Wei Chen, Yun-Chien Lin, Jenn-Wei Chen iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00515-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Jun-Jia Gong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Mitomycin, Metronidazole, Clostridioides difficile, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile is an anaerobic, spore-forming pathogen responsible for illnesses ranging from mild diarrhea to life-threatening colitis. Current treatments rely on antibiotics such as vancomycin and metronidazole (MTZ), but high doses can disrupt gut microbiota, contributing to recurrent infections. Mitomycin C (MMC), a Food and Drug Administration-approved anticancer agent, is known to induce prophage activation in lysogenic bacteria. Given that over 70% of C. difficile strains harbor prophages, we evaluated MMC’s potential to enhance antibiotic efficacy against C. difficile infection (CDI). In vitro , MMC synergized with MTZ to inhibit strain R20291 and clinical isolates of RT027 and RT078 while reducing the minimum bactericidal concentration of MTZ against biofilm-associated cells. Ex vivo assays using mouse fecal suspensions confirmed the enhanced killing effect of the combination. In a murine recurrence model, low-dose MTZ + MMC treatment significantly improved survival and reduced fecal spore counts compared to monotherapies or vancomycin. Importantly, the combination did not cause greater liver or kidney toxicity than other antibiotics and resulted in less colonic epithelial damage. Microbiota profiling revealed that MTZ + MMC better preserved gut microbial composition than standard treatments. These findings suggest that low-dose MTZ combined with MMC enhances antimicrobial efficacy while reducing toxicity and microbiota disruption, offering a promising strategy for CDI management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitomycinMetronidazoleClostridioides difficileAnti-Bacterial AgentsClostridium InfectionsAnimalsMiceVancomycinMicrobial Sensitivity TestsDrug SynergismDrug Therapy, CombinationBiofilmsFemaleHumansFeces

Stichwörter der Autor:innen

Clostridioides difficilemetronidazolemitomycin Crecurrencespore

Substanzen

MitomycinMetronidazoleAnti-Bacterial AgentsVancomycin

Autor:innen und Institutionen

  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA.
  • Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
  • Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, California, USA.

ORCID-Profile: Jun-Jia Gong, Yuan-Pin Hung, Jenn-Wei Chen

Förderung

  • National Science and Technology Council

Zitieren

APA

Gong, J. J., Huang, I. H., Hung, Y., Chen, Y. W., Lin, Y. C., & Chen, J. W. (2025). Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00515-25

Vancouver

Gong JJ, Huang IH, Hung Y, Chen YW, Lin YC, Chen JW. Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00515-25

BibTeX
@article{Gong2025,
  author = {Gong, Jun-Jia and Huang, I-Hsiu and Hung, Yuan-Pin and Chen, Yi-Wei and Lin, Yun-Chien and Chen, Jenn-Wei},
  title = {Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00515-25}
}
Kostenlos starten →